Leqvio (Inclisiran) and PPIs (Omeprazole, Pantoprazole): Drug Interaction Guide
Leqvio (inclisiran) is a small interfering RNA (siRNA) medicine given by subcutaneous injection to lower LDL cholesterol. Omeprazole and pantoprazole are oral proton pump inhibitors (PPIs) that suppress stomach acid. Based on how each drug is absorbed and cleared, there is no known pharmacokinetic or pharmacodynamic interaction between inclisiran and either PPI, and no dose adjustment for either drug is described in FDA labeling when they are used together.
The core answer and its boundary
Inclisiran (Leqvio) is not a substrate of cytochrome P450 enzymes and is not transported by common drug transporters such as P-glycoprotein; it is cleared primarily through nuclease-mediated degradation after being taken up by hepatocytes via the asialoglycoprotein receptor pathway. PPIs like omeprazole and pantoprazole cause drug interactions almost exclusively through gastric pH elevation (affecting oral drug dissolution) and, for omeprazole in particular, CYP2C19 inhibition. Because inclisiran is injected rather than swallowed and does not rely on either of these pathways, there is no established mechanism for a clinically meaningful interaction. This conclusion rests on the drugs' pharmacologic profiles as described in their respective FDA labels, not on a dedicated interaction study, and that gap should be disclosed to patients and prescribers rather than glossed over.
Why the route of administration matters here
Inclisiran is injected subcutaneously into the abdomen, upper arm, or thigh and is directed to liver cells, where it reduces PCSK9 protein production and increases LDL receptor recycling. It never passes through the stomach or intestine. PPIs work by irreversibly inhibiting the H+/K+-ATPase pump in gastric parietal cells, which raises stomach pH. That pH change is what allows PPIs to interfere with the dissolution and absorption of certain orally administered drugs (for example, some azole antifungals or specific formulations of tyrosine kinase inhibitors). Since inclisiran is never dissolved or absorbed in the stomach, this pathway is not relevant to it.
The FDA-approved prescribing information for Leqvio describes inclisiran as not metabolized by cytochrome P450 enzymes and not a substrate for major drug transporters (FDA Leqvio label). This is the strongest available evidence for the absence of an interaction: it rules out the two mechanisms responsible for most PPI-related drug interactions.
What FDA labeling for omeprazole and pantoprazole says
Omeprazole's label lists specific interacting drugs where CYP2C19 inhibition or pH-dependent absorption is clinically relevant, such as clopidogrel, methotrexate, and certain antifungals (FDA omeprazole label). Inclisiran does not appear in that list, and given its non-oral, non-CYP-dependent profile, there is no pharmacologic reason it would. Pantoprazole's label similarly identifies pH- and CYP-mediated interactions with oral drugs, and has a comparatively narrower interaction list than omeprazole because it is a weaker CYP2C19 inhibitor (FDA pantoprazole label). Neither label references inclisiran or injectable PCSK9-targeted therapies.
Whether a PPI is a strong or weak CYP2C19 inhibitor is not relevant to inclisiran, because inclisiran does not use CYP enzymes for clearance under either drug's mechanism.
What is established, what is plausible, and what is not confirmed
The distinction between "no interaction is expected" and "an interaction has been tested for and ruled out" matters for a YMYL medical claim. Readers and clinicians should not treat this as equivalent to a completed drug-drug interaction study.
Evidence-status assessment: inclisiran plus omeprazole or pantoprazole
| Question | Status | Basis |
|---|---|---|
| Does inclisiran pass through the GI tract? | Established | Route of administration is subcutaneous injection, per FDA labeling |
| Does inclisiran depend on CYP450 metabolism? | Established | FDA label states it is not a CYP substrate |
| Does inclisiran depend on P-glycoprotein or other major transporters? | Established | FDA label states it is not a transporter substrate |
| Do PPIs' known interaction mechanisms (gastric pH, CYP2C19) apply to inclisiran? | Established as not applicable | Mechanistic mismatch confirmed by both drugs' labels |
| Has a dedicated inclisiran-PPI pharmacokinetic interaction study been published? | Not established | No such study is referenced in FDA labeling or identified for this review; absence of testing is not the same as a negative trial result |
| Do large inclisiran trials show reduced LDL-lowering efficacy in patients on PPIs? | Not established from a source available here | Trial populations were on multiple concomitant medications, but PPI-specific subgroup outcomes are not verified in the sources reviewed for this article |
| Could a PPI's separate effects (e.g., long-term magnesium depletion) matter for a patient's overall cardiovascular risk while on Leqvio? | Plausible but indirect | This would be a PPI-specific effect unrelated to any interaction with inclisiran itself |
What a clinician or pharmacist should verify before treating this as settled: confirm the current FDA label language for Leqvio has not changed regarding drug interactions, and check whether any post-marketing signal or updated label revision has since identified an interaction that was not present at initial approval. This is a normal step for any relatively new biologic or siRNA agent, since interaction data can accumulate after launch.
Practical guidance for patients taking both
Patients on a daily PPI who are prescribed Leqvio do not need to stop, switch, or time their PPI dose around the injection. The injection schedule, an initial dose, a second dose around three months later, then every six months, does not change based on PPI use, PPI dose, or which PPI is used. Switching between omeprazole, pantoprazole, another PPI, or an H2 blocker such as famotidine does not require any adjustment to the Leqvio regimen, because none of these acid-suppressing drugs act through a pathway inclisiran depends on.
This does not mean PPIs are risk-free in patients with cardiovascular disease. Long-term PPI use has been associated with lower magnesium levels in some patients, particularly with use beyond a year, and low magnesium can be relevant to arrhythmia risk. That is a reason to periodically reassess whether ongoing PPI therapy is still needed and to check magnesium if clinically indicated, especially in patients also on diuretics or digoxin. It is a matter of routine PPI stewardship, not evidence of an inclisiran interaction.
Where inclisiran's interaction profile fits among lipid drugs
Oral lipid-lowering drugs vary widely in how much they depend on the pathways PPIs affect. Statins metabolized through CYP3A4 (such as simvastatin or lovastatin) have more theoretical exposure to CYP-mediated interactions than injectable therapies. PCSK9 monoclonal antibodies (evolocumab, alirocumab), like inclisiran, are also injected and bypass GI absorption and CYP metabolism, so they share a similarly low interaction profile with PPIs. This is a general pharmacologic pattern rather than a claim backed by a head-to-head interaction trial, and readers should treat it as background context rather than a guarantee specific to any individual regimen.
When to involve a clinician
Anyone starting Leqvio should give their prescriber a complete list of medications, including over-the-counter PPIs, so the care team can screen for interactions among all drugs being taken together, not because a specific inclisiran-PPI concern is expected. Report any new or worsening symptoms after starting either drug, including unusual injection-site reactions (redness, pain, or rash near the injection site, which is the most commonly reported Leqvio-specific side effect) or new gastrointestinal symptoms while on a PPI. Seek urgent care for signs of a serious allergic reaction, such as swelling of the face or throat or difficulty breathing, after any injection.
Common questions
Can I take Leqvio with omeprazole or pantoprazole? There is no known mechanism for these drugs to interact, based on FDA labeling for all three medications. No dedicated interaction trial has been identified confirming this directly, so the answer rests on pharmacologic reasoning rather than a completed study.
Do I need to stop my PPI before a Leqvio injection? No. Nothing in current labeling for either drug calls for stopping or timing a PPI dose around a Leqvio injection.
Does omeprazole's stronger CYP2C19 inhibition matter more than pantoprazole's for Leqvio? No. Since inclisiran does not use CYP2C19 or any CYP enzyme for clearance, the difference between a strong and weak CYP2C19 inhibitor is not relevant to it.
What should I ask my doctor or pharmacist about this combination? Ask whether the current Leqvio label (checked against the version in effect at the time of your visit) has added any new interaction warnings since your prescription was written, and whether long-term PPI use warrants a periodic magnesium check given your other medications.
References
- Novartis Pharmaceuticals. Leqvio (inclisiran) prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214012lbl.pdf
- U.S. Food and Drug Administration. Omeprazole prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s096lbl.pdf
- U.S. Food and Drug Administration. Pantoprazole prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020987s045lbl.pdf
Note for editorial and clinical review: the source draft this article replaces included PubMed identifiers, specific trial percentages, and two attributed quotations (from a named ORION investigator and a named cardiologist) that could not be verified against retrievable primary literature for this rewrite. Those quotations and unverified numeric claims have been removed rather than carried forward. Before publication, please confirm current FDA label interaction language for Leqvio, omeprazole, and pantoprazole, and verify or reinstate any trial-specific efficacy figures against the original ORION-10/ORION-11 publications if they are to be included.